Şunu aradınız:: ublindet (Danca - İngilizce)

i et randomiseret, ublindet studie blev 32 kvinder behandlet i 6 cyklusser med ioa.
in a randomized, open label trial, 32 women were treated for 6 cycles with ioa.

heraf var de fire dobbeltblinde placebokontrollerede studier, mens ét var et ublindet- studie.
of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.

sikkerhed og virkning af axitinib er blevet undersøgt i et ublindet, multicenter fase 3-studie.
the safety and efficacy of axitinib were evaluated in a randomised, open-label, multicenter phase 3 study.

i alt 136, 21 og 82 patienter fik mindst én ublindet dosis i henholdsvis forsøg 301, 301ext og 302ext.
a total of 136, 21, and 82 patients received at least one open-label dose in studies 301, 301ext, and 302ext, respectively.

studiet var ublindet baseret på størrelsesordenen af observeret klinisk nytte, og patienterne i placebogruppen blev tilbudt behandling med zytiga.
the study was unblinded based on the magnitude of clinical benefit observed and patients in the placebo group were offered treatment with zytiga.

ved sygdomsprogression blev randomiseringskoden brudt, og placebo-patienter fik tilbudt ublindet behandling med sunitinib i et særskilt forlængelsesstudie.
upon disease progression, patients were unblinded and placebo patients were offered access to open-label sunitinib in a separate extension study.

heraf var fire studier dobbelt- blindede placebo- kontrollerede studier, og et studie var et ublindet studie.
survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open- label study.

i begge studier medførte oral og intravenøs topotecan samme symptomlindring hos patienter med recidiverende, sensitiv sclc i henhold til patienternes egne rapporteringer på en ublindet symptomskala.
oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive sclc in patient self- reports on an unblinded symptom scale assessment in each of these two studies.

i patienternes egne rapporteringer vha. en ublindet vurdering på en symptomskala i begge forsøg var oral og intravenøs topotecan forbundet med samme symptomlindring hos patienter med recidiverende, sensitiv sclc.
oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive sclc in patient self reports on an unblinded symptom scale assessment in each of these two studies.

i patienternes egne rapporteringer vha. en ublindet vurdering på en symptomskala i begge forsøg, var oral og iv topotecan forbundet med samme symptomlindring hos patienter med recidiverende, sensitiv sclc.
oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive sclc in patient self- reports on an unblinded symptom scale assessment in each of these two studies.

i patienternes egne rapporteringer vha. en ublindet vurdering på en symptomskala i begge forsøg, var oral og i. v. topotecan forbundet med samme symptomlindring hos patienter med recidiverende, sensitiv sclc.
one phase 2 study (study 065) and one phase 3 study (study 396) were conducted to evaluate the efficacy of oral topotecan versus intravenous topotecan in patients who had relapsed ≥ 90 days after completion of one prior regimen of chemotherapy. (see table 1) oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive sclc in patient self- reports on an unblinded symptom scale assessment in each of these two studies.

alle patienter havde tidligere responderet på duloxetin i en ublindet duloxetin-behandlingsperiode (28 til 34 uger) med en dosis på 60 til 120 mg/dag.
all patients had previously responded to duloxetine during open-label duloxetine treatment (28 to 34 weeks) at a dose of 60 to 120 mg/day.

effekten af eperzan blev vurderet i et randomiseret, ublindet, non-inferioritets-multicenterstudie (n = 563) af 52 ugers varighed.
the efficacy of eperzan was evaluated in a 52 week, randomised, open-label, multicentre noninferiority study (n = 563).

overlevelse og tumorprogression har været undersøgt i fem store kontrollerede studier, som i alt involverede 2833 patienter.heraf var fire studier dobbelt-blindede placebo-kotrollerede studier, og et studie var et ublindet studie.
survival and tumour progression have been examined in five large controlled studies involving a total of 2833 patients, of which four were double-blind placebo-controlled studies and one was an open-label study.